Romiplostim study and retrospective patients characteristics
| Characteristic . | Romiplostim, N (%) . | Retrospective, N (%) . |
|---|---|---|
| Number of patients (total) | 59 | 853 |
| Age, median (range) | 63 (24-75) | 60 (19-80) |
| Sex | ||
| Male | 34 (58) | 503 (59) |
| Female | 25 (42) | 350 (41) |
| Disease | ||
| Multiple myeloma | 40 (68) | 484 (57) |
| NHL or HL | 19 (32) | 369 (43) |
| Conditioning regimen | ||
| Melphalan | 40 (68) | 484 (57) |
| BEAM | 16 (27) | 296 (35) |
| TBC | 3 (5) | 73 (8) |
| CD34+ cell dose (× 10E6/kg), median (range) | 5.2 (2.9-8.7) | 5.1 (1.47-16.3) |
| Characteristic . | Romiplostim, N (%) . | Retrospective, N (%) . |
|---|---|---|
| Number of patients (total) | 59 | 853 |
| Age, median (range) | 63 (24-75) | 60 (19-80) |
| Sex | ||
| Male | 34 (58) | 503 (59) |
| Female | 25 (42) | 350 (41) |
| Disease | ||
| Multiple myeloma | 40 (68) | 484 (57) |
| NHL or HL | 19 (32) | 369 (43) |
| Conditioning regimen | ||
| Melphalan | 40 (68) | 484 (57) |
| BEAM | 16 (27) | 296 (35) |
| TBC | 3 (5) | 73 (8) |
| CD34+ cell dose (× 10E6/kg), median (range) | 5.2 (2.9-8.7) | 5.1 (1.47-16.3) |
BEAM, carmustine, etoposide, cytarabine, melphalan; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; TBC, thiotepa, busulfan, cyclophosphamide.